Insider Cluster (2 insiders) ·Filed Mar 26, 2026

CGEN

COMPUGEN LTD
NEUTRAL
Impact 3/10
Horizondays Processed6mo ago
Insider cluster: 2 insiders, $37K total
Actionable Insight • Neutral

The insider activity is minor in scale and typical for executives managing option portfolios; no signal of distress or confidence. Monitor upcoming earnings or pipeline updates for material catalysts.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
CGEN ▲ +0.97% at T+60d
NEUTRAL call ✓ call won +0.97% · α vs SPY -12.98% · entry $2.06 → $2.08
Entry anchored
Mar 25, 03:58 PM ET
via exchange tick
T+1d
-0.97%
call -0.97% · α +0.71%
$2.04
settled 6mo ago
T+5d
+9.71%
call +9.71% · α +8.08%
$2.26
settled 6mo ago
T+20d
+50.49%
call +50.49% · α +39.82%
$3.10
settled 5mo ago
T+60d
+0.97%
call +0.97% · α -12.98%
$2.08
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Compugen CEO Ophir Eran sold $12.4K of stock and exercised two tranches of options, one at zero cost and another at $0.83 per share, while SVP Levine Zurit sold $24K of shares in a recent insider cluster totaling $37K. The sales represent less than 0.1% of the company's $214M market cap and are consistent with routine post-exercise selling.

Key Financial Metrics

Direction
selling
Total Value
$37.0K
Insiders
2

Key Facts

  • CEO Ophir Eran sold 5,625 shares for $12,413 on April 1, 2026, following the exercise of 11,250 options (5,625 at $0, 5,625 at $0.8292).
  • SVP Levine Zurit sold 11,900 shares for $24,000 on March 26, 2026.
  • Total insider selling in the past 7 days: $37,000 across two insiders.
  • All transactions occurred at market prices with no block discounts or unusual timing.

Financial Impact

$37,000 in total open-market sales, representing 0.017% of $214M market cap

insider ownershipshare count

Risk Factors

  • Minimal dilution from option exercises, but economically insignificant.
  • Perception risk if media mischaracterizes zero-cost option exercise as 'selling at $0'.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-CGEN-1775215810179
8 reports for CGEN
Performance horizon
Filters
Rows
Reports for CGEN — sortable, filterable
TypeNow
Aug 3, 2026
8w ago
6-K
NEUTRAL ★ 2/10
$2.38 $2.56▲ +7.56%▲ +6.33%$2.31 (−2.94%)
Aug 3, 2026
8w ago
6-K
NEUTRAL ★ 4/10
$2.38 $2.56▲ +7.56%▲ +6.33%$2.31 (−2.94%)
Jun 9, 2026
16w ago
EFFECT
NEUTRAL ★ 3/10
$2.02 $2.39▲ +18.32%▲ +16.87%$2.31 (+14.36%)
May 18, 2026
19w ago
6-K
NEUTRAL ★ 4/10
$2.86 $2.03▼ −29.02%▼ −30.60%$2.31 (−19.23%)
Apr 24, 2026
23w ago
Insider Cluster
NEUTRAL ★ 2/10
$3.10 $2.61▼ −15.81%▼ −19.83%$2.31 (−25.48%)
Apr 14, 2026
24w ago
Insider Cluster
NEUTRAL ★ 2/10
$2.88 $2.87▼ −0.35%▼ −6.64%$2.31 (−19.79%)
Apr 13, 2026
24w ago
144
NEUTRAL ★ 3/10
$2.76 $2.87▲ +3.99%▼ −3.74%$2.31 (−16.30%)
Mar 26, 2026
27w ago
Insider Cluster
NEUTRAL ★ 3/10
$2.06 $3.10▲ +50.49%▲ +39.82%$2.31 (+12.14%)
Showing 8 of 8

US Market Status

Market Closed — Opens Mon (65h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Apr 3, 2026